Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy
| Autor: | Abdul Manan, Riaz Ahmad, Muhammad Saeed Qureshi, Peter Natesan Pushparaj, Arif Malik, Muhammad Imran Naseer, Mahmood Rasool, Muhammad Asif |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Pathology
medicine.medical_specialty hypocalcaemia MDA medicine.disease_cause Superoxide dismutase chemistry.chemical_compound Hyperphosphatemia hyperkalaemia hyperuricaemia GSH Medicine oxidative stress SOD hyperphosphatemia biology business.industry Cancer General Medicine Glutathione Hypothesis Tumor lysis syndrome (TLS) medicine.disease Malondialdehyde Tumor lysis syndrome chemistry Catalase biology.protein Cancer research business Oxidative stress |
| Zdroj: | Bioinformation |
| ISSN: | 0973-2063 |
| Popis: | Tumor lysis syndrome (TLS) is characterized by hyperuricaemia, hyperphosphatemia, hyperkalaemia, as well as hypocalcaemia due to the breakdown of tumor cells undergoing cancer therapy (chemo/radio). Therefore it is of interest to evaluate oxidative stress using selective biological markers [Malondialdehyde (MDA), Superoxide Dismutase (SOD), Glutathione (GSH) and Catalase (CAT)] in TLS. We report the marked differences (statistically significant with control) observed among a selected set of biomarkers of oxidative stress (MDA = 8.66±1.37; SOD = 0.15±0.11; GSH = 2.25±.77; CAT = 0.76±.57) in TLS patients in addition to other conventional biomarkers. Moreover, correlation was investigated among the parameters of oxidative stress and other circulating biomarkers of TLS. Data suggest the use of SOD, MDA, and GSH as potential diagnostic biomarker for TLS with other biomarkers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|